Wait ...what ? Am I understanding this correctly ?
alterity now has to do a 1 year preclinical study prior to advancing discussions with FDA on endpoints for a p2 ?
has the MSA route ( chosen to speed things up ) now backfired as no way to measure efficacy of p2 trial due to lack of data available so alterity now has to first produce said data ?
please tell me I'm wrong
Ann: Meeting with US FDA provides development path for ATH434, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $88.06K | 8.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 11330464 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1574126 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |